Asa Abeliovich is Prevail’s Chief Executive Officer and Founder, bringing more than 25 years of academic and industry experience in research and the understanding of genetic and molecular mechanisms that underlie neurological disorders of aging, such as Parkinson’s disease. Prior to Prevail Therapeutics, Asa was Co-Founder of and consultant to Alector, a biotechnology company which is developing antibodies for the treatment of neurodegenerative diseases. Asa was previously a tenured Associate Professor of Pathology, Cell Biology, and Neurology at Columbia University, as well as a member of the Taub Institute for Alzheimer’s Disease and the Aging Brain. He has also previously served as an Attending Physician in Neurology at the New York-Presbyterian Hospital and the New York Psychiatric Institute. Asa was awarded the Lamport Award for Excellence in Basic Science Research at Columbia University in 2005. Asa is on the Scientific Advisory Board of The Silverstein Foundation for Parkinson’s with GBA.

Asa holds M.D. and Ph.D. degrees from Harvard Medical School and the Massachusetts Institute of Technology (MIT), respectively, and Bachelor’s degrees in life sciences and humanities from MIT. Asa was awarded a Medical Scholar Training Program Fellowship and completed his residency training in neurology at the University of California, San Francisco.